Rein Therapeutics Overview
- Year Founded
-
2001

- Status
-
Public
- Employees
-
3

- Stock Symbol
-
RNTX

- Investments
-
1
- Share Price
-
$2.44
- (As of Friday Closing)
Rein Therapeutics General Information
Description
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
Contact Information
Website
www.reintx.comCorporate Office
- 12407 North Mopac Expressway
- Suite 250 Number 390
- Austin, TX 78758
- United States
Corporate Office
- 12407 North Mopac Expressway
- Suite 250 Number 390
- Austin, TX 78758
- United States
Rein Therapeutics Timeline
Rein Therapeutics Stock Performance
As of 14-Feb-2025, Rein Therapeutics’s stock price is $2.44. Its current market cap is $52.9M with 21.7M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.44 | $2.35 | $1.61 - $7.42 | $52.9M | 21.7M | 102K | -$2.88 |
Rein Therapeutics Financials Summary
As of 30-Sep-2024, Rein Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 99,785 | 2,826 | (14,647) | (1,056) |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (29,070) | (15,957) | (27,160) | (26,043) |
Net Income | (29,241) | (15,732) | (27,329) | (26,164) |
Total Assets | 104,217 | 106,008 | 22,007 | 48,481 |
Total Debt | 0 | 48 | 33 | 162 |
Rein Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Rein Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Rein Therapeutics Comparisons
Industry
Financing
Details
Rein Therapeutics Competitors (134)
One of Rein Therapeutics’s 134 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
Tvardi Therapeutics | Venture Capital-Backed | Sugar Land, TX | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
TScan Therapeutics | Formerly VC-backed | Waltham, MA |
Rein Therapeutics Patents
Rein Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020241429-A1 | Peptidomimetic macrocycles and uses thereof | Inactive | 15-Mar-2019 | ||
US-20200289609-A1 | Peptidomimetic macrocycles and uses thereof | Inactive | 15-Mar-2019 | ||
EP-3938051-A4 | Peptidomimetic macrocycles and uses thereof | Inactive | 15-Mar-2019 | ||
EP-3938051-A1 | Peptidomimetic macrocycles and uses thereof | Inactive | 15-Mar-2019 | ||
CA-3132993-A1 | Peptidomimetic macrocycles and uses thereof | Pending | 15-Mar-2019 | A61K38/12 |
Rein Therapeutics Signals
Rein Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Rein Therapeutics Acquisitions (1)
Rein Therapeutics’s most recent deal was a Merger/Acquisition with Lung Therapeutics. The deal was made on 31-Oct-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Lung Therapeutics | 31-Oct-2023 | Merger/Acquisition | Drug Discovery |
Rein Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Lung Therapeutics | Austin, TX | 2013 |
Rein Therapeutics FAQs
-
When was Rein Therapeutics founded?
Rein Therapeutics was founded in 2001.
-
Where is Rein Therapeutics headquartered?
Rein Therapeutics is headquartered in Austin, TX.
-
What is the size of Rein Therapeutics?
Rein Therapeutics has 3 total employees.
-
What industry is Rein Therapeutics in?
Rein Therapeutics’s primary industry is Drug Discovery.
-
Is Rein Therapeutics a private or public company?
Rein Therapeutics is a Public company.
-
What is Rein Therapeutics’s stock symbol?
The ticker symbol for Rein Therapeutics is RNTX.
-
What is the current stock price of Rein Therapeutics?
As of 14-Feb-2025 the stock price of Rein Therapeutics is $2.44.
-
What is the current market cap of Rein Therapeutics?
The current market capitalization of Rein Therapeutics is $52.9M.
-
Who are Rein Therapeutics’s competitors?
Pliant Therapeutics, Tvardi Therapeutics, Kite Pharma, NexImmune, and TScan Therapeutics are some of the 134 competitors of Rein Therapeutics.
-
What is Rein Therapeutics’s annual earnings per share (EPS)?
Rein Therapeutics’s EPS for 12 months was -$2.88.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »